All episodes
Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
Ep. 295 - Bio€quity Europe 2025 Preview
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
Ep. 291 - Grand Rounds - U.S. Preview
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
Ep. 284 - Takeaways from the East-West Summit
Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
Ep. 279 - East-West Summit Preview
Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal
Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
Ep. 264 - Prepping for Trump & Alzheimer's Ethics
Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser
Ep. 262 - EGFR Case Study, FDA & Politics
Ep. 261 - China Summit: Reinventing Your China Strategy
Ep. 260 - VC Funds, New Chapter for MS, Wave's Data
Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA
Ep. 258 - Breaking the Bear: 4Q Public Markets Preview
Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update
Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary
Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss
Ep. 254 - Takeaways from Grand Rounds 2024
Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset
Ep. 251 - Eyes on the target: a Back to School Overview
Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery
Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update
Ep. 248 - Grand Rounds Preview: Eyes on the Target
Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School
Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds
Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On
Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers
Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs
Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns
Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure
Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner
Ep. 239 - Rare Disease Spotlight: MPS & DMD
Ep. 238 - Biosecure Act: The Impact & What's Ahead
Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS
Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma
Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations
Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update
Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A
Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data
Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note
Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
Ep. 230 - Bio€quity Europe 2024 Preview
Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure
Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera
Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss
Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves
Ep. 225 - 2Q Markets Preview & AACR Takeaways
Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS
Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs
Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts
Ep. 221 - China Biocontroversy, Plus: Diversity Matters
Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight
Ep. 219 - East-West Summit Preview
Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases
Ep. 217 - Safer CAR Ts & World’s First TIL Therapy
Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond
Ep. 215 - ADCs, Psychedelics & IPOs
Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech
Ep. 213 - Biotech IPOs & IL-18 Momentum
Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact
Ep. 211 - 2024 Markets Preview, Woodcock's Legacy
Ep. 210 - J.P. Morgan Healthcare Conference Wrap
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
Ep. 208 - XBI Rally, ASH Highlights & '24 Picks
Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in
Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T
Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech
Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans
Ep. 203 - POC for Verve? Plus: IRA & East-West Deals
Ep. 202 - A DMD Decision & Endpoint Innovation
Ep. 201 - ESMO, NIH & IRA